Table 1.
Pre- and post-operative characteristics of patients with absence or presence of lymph nodes in PAFP
| LN absent in PAFP | LN present in PAFP | P-value | |
|---|---|---|---|
| (N = 7891) | (N = 909) | ||
| Age, years: mean (SD) | 62.7 (7.5) | 62.9 (7.7) | 0.413 |
| BMI, kg/m2 :mean (SD) | 27.9 (3.7) | 27.9 (4.2) | 0.814 |
| PSA, ng/ml: mean (SD) | 8.84 (12.32) | 10.00 (24.62) | 0.107 |
| Categorical PSA, ng/ml: % | 0.814 | ||
| 0-3.9 | 20.0 | 22.0 | |
| 4-9.9 | 58.3 | 56.2 | |
| 10-20 | 15.1 | 14.0 | |
| >20 | 6.7 | 7.8 | |
| Biopsy GS: % | <0.001 | ||
| 6-7 | 82.8 | 78.3 | |
| 8-10 | 17.2 | 21.7 | |
| Pathologic GS: % | 0.307 | ||
| 6-7 | 83.8 | 82.1 | |
| 8-10 | 16.7 | 17.9 | |
| Pathologic T stage: % | 0.659 | ||
| T2≥ | 67.5 | 66.8 | |
| T3≤ | 32.5 | 33.2 | |
| Pathologic N stage: % | 0.001 | ||
| N0/Nx | 96.0 | 93.5 | |
| N1 | 4.0 | 6.5 | |
| Margin status: % | <0.001 | ||
| Negative | 82.3 | 78.1 | |
| Positive | 17.7 | 21.9 | |
PAFP, Prostate anterior fat pad; LN, Lymph node; BMI, Body mass index; PSA, Prostate-specific antigen; GS, Gleason score